Forecast: Idiopathic Pulmonary Fibrosis (IPF).
By Hardik Patel, Lead Analyst
13 January 2016
I am Lead Analyst for oncology at Datamonitor Healthcare, based in the New York office. I have a Bachelor of Science deg...
Read full bio
Datamonitor Healthcare forecasts that the branded Idiopathic pulmonary fibrosis (IPF) market over 2015-24 will grow at a compound annual growth rate of 12.1% across the US, Japan and five major EU markets*.
The primary drivers behind this market growth will be the continued use of high-priced approved brands (Esbriet and Ofev); as well as the rising number of diagnosed prevalent IPF cases, from 193,620 to 229,210 over 2015-24.
To provide you with an in-depth understanding of this market, Datamonitor Healthcare has produced a 10 year patient-based forecast using proprietary primary research and epidemiology information.
Explore our Idiopathic Pulmonary Fibrosis forecast by downloading your exclusive extract from this market leading report >>
If you’re already a subscriber to Datamonitor Healthcare, click here to access the full report.